Rosebud Biosciences GTM brain

Rosebud Biosciences develops mutation-specific human organoid models for drug discovery and partners with pharmaceutical and biotech teams, while pursuing therapies for pediatric genetic diseases.

category

Organoid drug discovery

market profile

  • text: Rare genetic diseases often lack targeted therapies, creating demand for disease-relevant preclinical models.
  • text: Organoid models are being used in drug discovery and safety assessment, including a collaboration with iXCells.

personas

  • title: Head of discovery biology at a rare disease biotech
    pains:
    • Animal and conventional cell models may not reproduce a patient's mutation or developmental phenotype.
    • Small patient populations make target validation difficult.
  • title: Pharma translational science or toxicology director
    pains:
    • Drug teams need human tissue models to evaluate candidate effects before clinical studies.
    • Models must be reproducible enough to scale across compounds.

icp

  • text: Pharmaceutical and biotechnology teams developing genetic disease therapies or assessing tissue-specific drug effects.
  • text: Organizations with iPSC capabilities or patient-derived cells that need organoid generation and screening partners.

message pillars

  • text: Model the patient's mutation in human developmental biology.
  • text: Use human organoids for multiple therapeutic modalities.
  • text: Scale discovery using automation and analytics.

objections

  • objection: Will the model reproduce the biology of our disease?
    response: Scope a pilot around the specific mutation, phenotype, controls and relevant readouts before broader screening.
  • objection: Can a 3D model support reproducible screening at useful scale?
    response: Review assay variability, throughput and longitudinal imaging on a representative compound set.

competitors

  • name: HeartBeat.bio
    why: Cardiac organoid-based drug discovery overlaps with Rosebud's cardiac models.
  • name: Molecular Devices
    why: Offers custom organoid expansion services for high-throughput applications.

keywords

  • patient specific organoid screening
  • iPSC disease modeling
  • cardiac organoid drug discovery
  • rare genetic disease models
  • organoid toxicology screening
  • pediatric drug discovery

voice

  • mission-driven
  • scientific
  • patient-centered

signals

  • text: A biotech launches a rare genetic disease program and needs mutation-specific models.
  • text: A pharma team seeks human organoid toxicology models for investigational compounds.

stack

  • human induced pluripotent stem cells
  • live cell microscopy

pricing

model: unknown

motion

sales_led

channels

  • partnerships
  • industry events
  • LinkedIn

confidence

medium

Founders

  • name: Kitch Wilson
    title: Founder
    role: Founder
    bio: Kitch is CEO and co-founder of Rosebud Biosciences. He is a Physician-Scientist (MD, PhD) with 16 years’ experience merging human induced pluripotent stem cells with genomic and molecular technologies. A Stanford-trained molecular pathologist, Kitch was an attending physician at Stanford for 6 years before cofounding Rosebud.
  • name: Evan Lyall
    title: Founder
    role: Founder
    bio: Evan is co-founder and CTO of Rosebud Biosciences. Evan is a Scientist-Engineer (PhD) with 10 years’ experience in advanced microscopy, machine learning, and data engineering. At UC Berkeley he studied the neural coding of perception and was part of a team that built the first bidirectional brain machine interface with proven single cell resolution. Before joining Rosebud he contracted for startups as a data and ML engineer.

Back to YC companies